RFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICSRFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICS
Home/Compounds/TB-500
Healing

TB-500

Also known as: Thymosin Beta-4 · TB4 · Timbetasin

Synthetic fragment of thymosin beta-4 studied for tissue repair, wound healing, and recovery.

B
Grade B
Human observational studies
Human studies26
PubMed citations30
Typical dose2 mg – 5 mg
Routesubcutaneous, intramuscular
Regulatory (US)Compounding legal
Last verifiedyesterday
TL;DR · 30-second summary
  • Accelerated wound healing in human venous ulcer trials
  • Improved outcomes in dry eye disease
  • Anti-inflammatory effects demonstrated
  • Enhanced cardiac function post-MI in animal studies

Mechanism of action

Promotes cell migration, blood vessel formation, and reduces inflammation. Upregulates actin, enabling cell migration to injury sites. Modulates inflammatory cytokines.

Evidence summary

26
Human studies
30
PubMed citations
0
Clinical trials
B
Evidence grade

Human trials in wound healing (venous stasis ulcers, epidermolysis bullosa) and dry eye show promising results. Phase 2 trials completed for several indications.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
2 mg – 5 mg

Research protocols typically use 2-5mg 2x weekly during loading phase, then weekly for maintenance. Duration varies by application.

Administration routes
subcutaneousintramuscular

Side effects & safety

Reported side effects
Head rush/lightheadednessPossible lethargyInjection site reactions
Contraindications
  • Active cancer (theoretical concern)
  • Pregnancy/nursing

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Not FDA approved. Research chemical. Category 2 nomination pending.

Compounding
Permitted

Available through compounding pharmacies with valid prescription.

Regulatory data last verified 4/17/2026

Citations

PMID 41570941Di H, Huang J et al. · Thymosin beta 4: An emerging therapeutic candidate for kidney diseases.Peptides (2026)HumanPMID 41476424Mayfield CK, Bolia IK et al. · Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.The American journal of sports medicine (2026)HumanPMID 41490200Rahman OF, Lee SJ et al. · Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)HumanPMID 41235866Nguyen J, Verma S et al. · Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing.Investigative ophthalmology & visual science (2025)HumanPMID 39837870Chen X, Zhang C et al. · Identification of glutamine as a potential therapeutic target in dry eye disease.Signal transduction and targeted therapy (2025)HumanPMID 39761767Zhang X, Lin Y et al. · Enhancing fat graft survival: thymosin beta-4 facilitates mitochondrial transfer from ADSCs via tunneling nanotubes by upregulating the Rac/F-actin pathway.Free radical biology & medicine (2025)HumanPMID 36831151Singh SK, Dwivedi SD et al. · Novel Biotherapeutics Targeting Biomolecular and Cellular Approaches in Diabetic Wound Healing.Biomedicines (2023)HumanPMID 36720193Naeem A, Knoer G et al. · Provocative non-canonical roles of p53 and AKT signaling: A role for Thymosin β4 in medulloblastoma.International immunopharmacology (2023)HumanPMID 35675640Tiedemann K, Tsao S et al. · Platelets and osteoblasts: secretome connections.American journal of physiology. Cell physiology (2022)PMID 35842494Mason WJ, Jafree DJ et al. · Systemic gene therapy with thymosin β4 alleviates glomerular injury in mice.Scientific reports (2022)HumanPMID 34324435Lee E, Padgett B · Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine (2021)HumanPMID 34335970Tan SH, Loo SJ et al. · Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction.Theranostics (2021)HumanPMID 33967626Yu R, Mao Y et al. · Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection.Mediators of inflammation (2021)HumanPMID 31702404Aksu U, Yaman OM et al. · The Protective Effects of Thymosin-β-4 in a Rat Model of Ischemic Acute Kidney Injury.Journal of investigative surgery : the official journal of the Academy of Surgical Research (2021)PMID 31819429Fu X, Shi Y et al. · Ethosomal Gel for Improving Transdermal Delivery of Thymosin β-4.International journal of nanomedicine (2020)HumanPMID 30063846Gupta S, Li L · The role of Thymosin β4 in angiotensin II-induced cardiomyocytes growth.Expert opinion on biological therapy (2019)HumanPMID 29864245Weinberger F, Nicol P et al. · No effect of thymosin beta-4 on the expression of the transcription factor Islet-1 in the adult murine heart.Pharmacology research & perspectives (2018)HumanPMID 27130465Gao XY, Hou F et al. · Role of thymosin beta 4 in hair growth.Molecular genetics and genomics : MGG (2017)PMID 27450736Pipes GT, Yang J · Cardioprotection by Thymosin Beta 4.Vitamins and hormones (2017)HumanPMID 28127198Zheng XY, Lv YF et al. · Recombinant adeno-associated virus carrying thymosin β4 suppresses experimental colitis in mice.World journal of gastroenterology (2017)Human

Showing 20 of 30 papers. View all on PubMed →